The amplification frequencies of LANCL2 and EGFR in GBM were up to 27.65% (159 of 575 cases) and 44.35% (255 of 575 cases), whereas those in low-grade glioma (LGG) were only 3.91% (20 of 511 cases) and 7.63% (39 of 511 cases), respectively (Fig. 1C). Here, EGFR is linked to central nervous system cancer.